- Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
- Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
- HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Key statistics
On Friday, HCW Biologics Inc (HCWB:NMQ) closed at 1.10, 20.88% above the 52 week low of 0.91 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.10 |
---|---|
High | 1.16 |
Low | 1.10 |
Bid | 1.01 |
Offer | 1.17 |
Previous close | 1.10 |
Average volume | 34.64k |
---|---|
Shares outstanding | 37.82m |
Free float | 17.85m |
P/E (TTM) | -- |
Market cap | 41.61m USD |
EPS (TTM) | -0.6953 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼